Dexamethasone palmitate has the potential to inhibit the activity of tumor-associated macrophages, which promote
cancer proliferation, invasion, and
metastasis; however, only very high and frequent doses are capable of inducing antitumor effects. With the aim to reduce the anticancer dose and decrease the nonspecific toxicity, we designed a liposomal system to co-deliver
dexamethasone palmitate and
doxorubicin. Furthermore, a
ligand conjugate
sialic acid-
octadecylamine, with enhanced affinity towards the membrane receptors over-expressed in
tumors, was anchored on the surface of the
liposomes to increase drug distribution to the
tumor tissue. Co-loaded
liposomes were developed using
lipid film hydration method to load
dexamethasone palmitate and remote loading technology to load
doxorubicin. The co-loaded
liposomes modified with
sialic acid-
octadecylamine represented comparable physicochemical properties and blood plasma profiles with conventional co-loaded
liposomes, but the biodistribution proved that
sialic acid-
octadecylamine modified
liposomes accumulated more in
tumor. The co-loaded
liposomes showed higher
tumor growth suppression than the single-drug loaded
liposomes, while showing no additional
drug toxicity in S180-bearing Kunming mice. The co-loaded
liposomes modified with
sialic acid-
octadecylamine achieved a significantly better antitumor effect, and induced "shedding" of cancerous tissue in the mice. These finding suggested that co-loaded
liposomes modified with
sialic acid-
octadecylamine provided a safe therapeutic strategy with outstanding anticancer activity.